Seres Therapeutics Inc Total Liabilities
Seres Therapeutics Inc total liabilities. Based on the latest financial reports, Seres Therapeutics Inc (MCRB) has total liabilities worth $67.05 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MCRB asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Seres Therapeutics Inc (2012–2025)
Total liabilities of Seres Therapeutics Inc from 2012 to 2025. This chart illustrates how Seres Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore MCRB strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Seres Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Seres Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asia Technology Co Ltd
KQ:050860
|
Korea | ₩81.51 Billion |
|
BOXABL Inc.
NASDAQ:BXBL
|
USA | $13.64 Million |
|
ATA Creativity Global
NASDAQ:AACG
|
USA | $403.71 Million |
|
AJ Advance Technology Public Company Limited
BK:AJA
|
Thailand | ฿117.86 Million |
|
Puncak Niaga Holdings Bhd
KLSE:6807
|
Malaysia | RM1.49 Billion |
|
SCI Electric Public Company Limited
BK:SCI
|
Thailand | ฿911.77 Million |
|
Gensight Biologics SA
PA:SIGHT
|
France | €33.20 Million |
|
INSPIREMD 1/18 DL-0001
F:II2
|
Germany | €14.20 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Seres Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Seres Therapeutics Inc's balance sheet.
Liquidity & Leverage Metrics
Seres Therapeutics Inc Total Liabilities Ratios Explained
Seres Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Seres Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Seres Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Seres Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $93.97 Million | -25.43% |
| 2024-12-31 | $126.03 Million | -68.76% |
| 2023-12-31 | $403.46 Million | +19.37% |
| 2022-12-31 | $338.00 Million | +51.33% |
| 2021-12-31 | $223.35 Million | +32.80% |
| 2020-12-31 | $168.19 Million | -6.96% |
| 2019-12-31 | $180.76 Million | +7.27% |
| 2018-12-31 | $168.52 Million | +30.81% |
| 2017-12-31 | $128.82 Million | -7.99% |
| 2016-12-31 | $140.01 Million | +1116.89% |
| 2015-12-31 | $11.51 Million | -92.01% |
| 2014-12-31 | $144.07 Million | +9542.97% |
| 2013-12-31 | $1.49 Million | +739.33% |
| 2012-12-31 | $178.00K | -- |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pat… Read more